William Blair starts Kyverna coverage with Outperform, citing KYV-101’s potential as the first FDA-approved CAR-T therapy in autoimmune disease.
William Blair starts Kyverna coverage with Outperform, citing KYV-101’s potential as the first FDA-approved CAR-T therapy in autoimmune disease.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.